Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. reports a material definitive agreement entered into on January 14, 2019. The report was filed on January 15, 2019.
Key Financial Metrics
The filing details an underwritten public offering of common stock with the following terms:
- Shares Offered: 5,000,000 shares of common stock.
- Offering Price: $77.50 per share to the public.
- Underwriter Purchase Price: $76.46 per share.
- Expected Net Proceeds: Approximately $382 million (after underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: The underwriter (Barclays Capital Inc.) has a 30-day option to purchase up to an additional 750,000 shares at the same price to cover over-allotments.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics as this is a transaction report rather than a periodic financial statement.
Material Changes
The primary material change is the execution of an underwriting agreement to raise capital through a primary equity offering. The transaction is expected to close on January 17, 2019, subject to customary closing conditions.
Outlook and Risks
The offering is expected to close on January 17, 2019. The net proceeds are contingent on the satisfaction of closing conditions and the potential exercise of the over-allotment option by the underwriter. The filing incorporates by reference the Underwriting Agreement and a press release for further details.
Investor Verification Checklist
- Verify the final closing date of the offering (expected January 17, 2019).
- Confirm whether the underwriter exercises the option to purchase the additional 750,000 shares.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific terms and conditions.
- Check the press release (Exhibit 99.1) for management's stated use of proceeds.